Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper

Produktnummer ABIN7487776

Produktdetails anti-MS4A1 (Rituximab Biosimilar) Antikörper

Target: MS4A1 (Rituximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Mammalian Cells

Expressionssystem: Mammalian cells

Klonalität: Monoklonal

Konjugat: Dieser MS4A1 (Rituximab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA

Verwendungszweck: Rituximab Biosimilar - Anti-MS4A1 mAb

Produktmerkmale: Antibody Type: IgG1

Aufreinigung: Recombinant antibody expressed in mammalien cells and purified.

Güteklasse: Research Grade

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS pH 7.5

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: 4°C for short term, -20°C for long term

Details zu MS4A1 (Rituximab Biosimilar)

Target: MS4A1 (Rituximab Biosimilar)

Abstract: MS4A1 (Rituximab Biosimilar) Produkte

Synonyme: B1 antikoerper, Bp35 antikoerper, CD20 antikoerper, CVID5 antikoerper, LEU-16 antikoerper, MS4A2 antikoerper, S7 antikoerper, membrane spanning 4-domains A1 antikoerper, MS4A1 antikoerper

Substanzklasse: Biosimilar

Hintergrund: Rituximab
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers.